Due to the destructive nature of COPD on patients’ lungs and well-being, timely diagnosis is key, and integrating spirometry ...

Significantly greater composite adverse outcome rates seen for long- versus short-term inhaled corticosteroid use for prevalent, inception cohorts.

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Medically reviewed by Sanja Jelic, MD Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory (lung) ...

Early diagnosis of COPD, chronic obstructive pulmonary disease, increases the quality of life of the patient and the efficacy ...

Many people with COPD have other conditions like diabetes or high cholesterol, too. Managing several conditions can be ...

Dupixent for the treatment of COPD has been approved in more than 45 countries worldwide, including the 27 member countries of the European Union (EU). COPD is a chronic respiratory disease that ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD ...